S&P 500   4,337.94 (+0.18%)
DOW   34,071.93 (+0.00%)
QQQ   359.71 (+0.52%)
AAPL   175.03 (+0.63%)
MSFT   319.97 (+0.14%)
META   303.23 (+2.54%)
GOOGL   131.17 (+0.56%)
AMZN   130.97 (+1.27%)
TSLA   254.81 (-0.35%)
NVDA   414.75 (+1.12%)
NIO   8.61 (+1.89%)
BABA   88.27 (+4.95%)
AMD   96.47 (+0.37%)
T   15.12 (-1.24%)
F   12.63 (+3.52%)
MU   68.93 (+1.52%)
CGC   0.82 (+7.16%)
GE   112.99 (+0.00%)
DIS   82.66 (-0.08%)
AMC   7.71 (+0.13%)
PFE   32.63 (-0.67%)
PYPL   58.67 (+0.09%)
NFLX   382.45 (-0.44%)
S&P 500   4,337.94 (+0.18%)
DOW   34,071.93 (+0.00%)
QQQ   359.71 (+0.52%)
AAPL   175.03 (+0.63%)
MSFT   319.97 (+0.14%)
META   303.23 (+2.54%)
GOOGL   131.17 (+0.56%)
AMZN   130.97 (+1.27%)
TSLA   254.81 (-0.35%)
NVDA   414.75 (+1.12%)
NIO   8.61 (+1.89%)
BABA   88.27 (+4.95%)
AMD   96.47 (+0.37%)
T   15.12 (-1.24%)
F   12.63 (+3.52%)
MU   68.93 (+1.52%)
CGC   0.82 (+7.16%)
GE   112.99 (+0.00%)
DIS   82.66 (-0.08%)
AMC   7.71 (+0.13%)
PFE   32.63 (-0.67%)
PYPL   58.67 (+0.09%)
NFLX   382.45 (-0.44%)
S&P 500   4,337.94 (+0.18%)
DOW   34,071.93 (+0.00%)
QQQ   359.71 (+0.52%)
AAPL   175.03 (+0.63%)
MSFT   319.97 (+0.14%)
META   303.23 (+2.54%)
GOOGL   131.17 (+0.56%)
AMZN   130.97 (+1.27%)
TSLA   254.81 (-0.35%)
NVDA   414.75 (+1.12%)
NIO   8.61 (+1.89%)
BABA   88.27 (+4.95%)
AMD   96.47 (+0.37%)
T   15.12 (-1.24%)
F   12.63 (+3.52%)
MU   68.93 (+1.52%)
CGC   0.82 (+7.16%)
GE   112.99 (+0.00%)
DIS   82.66 (-0.08%)
AMC   7.71 (+0.13%)
PFE   32.63 (-0.67%)
PYPL   58.67 (+0.09%)
NFLX   382.45 (-0.44%)
S&P 500   4,337.94 (+0.18%)
DOW   34,071.93 (+0.00%)
QQQ   359.71 (+0.52%)
AAPL   175.03 (+0.63%)
MSFT   319.97 (+0.14%)
META   303.23 (+2.54%)
GOOGL   131.17 (+0.56%)
AMZN   130.97 (+1.27%)
TSLA   254.81 (-0.35%)
NVDA   414.75 (+1.12%)
NIO   8.61 (+1.89%)
BABA   88.27 (+4.95%)
AMD   96.47 (+0.37%)
T   15.12 (-1.24%)
F   12.63 (+3.52%)
MU   68.93 (+1.52%)
CGC   0.82 (+7.16%)
GE   112.99 (+0.00%)
DIS   82.66 (-0.08%)
AMC   7.71 (+0.13%)
PFE   32.63 (-0.67%)
PYPL   58.67 (+0.09%)
NFLX   382.45 (-0.44%)
NASDAQ:ABEO

Abeona Therapeutics (ABEO) Stock Forecast, Price & News

$3.80
+0.19 (+5.26%)
(As of 09:50 AM ET)
Compare
Today's Range
$3.61
$3.80
50-Day Range
$2.98
$4.43
52-Week Range
$2.19
$5.80
Volume
8,448 shs
Average Volume
163,159 shs
Market Capitalization
$94.09 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$38.00

Abeona Therapeutics MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
952.6% Upside
$38.00 Price Target
Short Interest
Healthy
2.17% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.03
Upright™ Environmental Score
News Sentiment
1.08mentions of Abeona Therapeutics in the last 14 days
Based on 3 Articles This Week
Insider Trading
Acquiring Shares
$11,400 Bought Last Quarter
Proj. Earnings Growth
Growing
From ($1.99) to ($1.77) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.57 out of 5 stars

Medical Sector

132nd out of 965 stocks

Pharmaceutical Preparations Industry

44th out of 451 stocks


ABEO stock logo

About Abeona Therapeutics (NASDAQ:ABEO) Stock

Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B. It is also developing ABO-201 gene therapy for juvenile Batten disease; ABO-202 gene therapy for treatment of infantile Batten disease; EB-201 for for epidermolysis bullosa (EB); ABO-301 for Fanconi anemia disorder; and ABO-302 using a novel CRISPR/Cas9-based gene editing approach to gene therapy program for rare blood diseases. Further, it is involved in marketing MuGard, a mucoadhesive oral wound rinse for the management of mucositis, stomatitis, aphthous ulcers, and traumatic ulcers. Abeona Therapeutics Inc. has collaborations with EB Research Partnership and Epidermolysis Bullosa Medical Research Foundation that focus on gene therapy treatments for EB; and Brammer Bio for commercial translation of ABO-102. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was incorporated in 1989 and is based in Dallas, Texas.

ABEO Price History

ABEO Stock News Headlines

3 Biotech Blockbusters to Turn $5,000 Into $50,000
The single greatest medical breakthrough of all time?
We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.
The single greatest medical breakthrough of all time?
We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.
ABEO: On Track to File BLA in 3Q23...
See More Headlines
Receive ABEO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Abeona Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ABEO Company Calendar

Last Earnings
8/08/2023
Today
9/22/2023
Next Earnings (Estimated)
11/13/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ABEO
Previous Symbol
OTCMKTS:ACCP
Employees
N/A
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$38.00
High Stock Price Forecast
$38.00
Low Stock Price Forecast
$38.00
Forecasted Upside/Downside
+952.6%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-39,700,000.00
Pretax Margin
-1,101.91%

Debt

Sales & Book Value

Annual Sales
$1.41 million
Book Value
$1.56 per share

Miscellaneous

Free Float
23,939,000
Market Cap
$89.38 million
Optionable
Optionable
Beta
1.29
5G Stocks: The Path Forward is Profitable Cover

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Key Executives

  • Mr. Steven H. Rouhandeh (Age 61)
    Exec. Chairman
  • Dr. Timothy J. Miller (Age 46)
    Pres, Chief Scientific Officer & Director
  • Mr. Jeffrey Blaine Davis (Age 55)
    Chief Operating Officer
  • Mr. Carsten Thiel (Age 54)
    Chief Exec. Officer
  • Mr. Stephen B. Thompson (Age 64)
    Sr. VP of Fin. and Admin., Chief Accounting Officer, Sec. & Treasurer













ABEO Stock - Frequently Asked Questions

Should I buy or sell Abeona Therapeutics stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Abeona Therapeutics in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" ABEO shares.
View ABEO analyst ratings
or view top-rated stocks.

What is Abeona Therapeutics' stock price forecast for 2023?

1 brokers have issued 1-year price targets for Abeona Therapeutics' stock. Their ABEO share price forecasts range from $38.00 to $38.00. On average, they expect the company's stock price to reach $38.00 in the next year. This suggests a possible upside of 952.6% from the stock's current price.
View analysts price targets for ABEO
or view top-rated stocks among Wall Street analysts.

How have ABEO shares performed in 2023?

Abeona Therapeutics' stock was trading at $3.08 at the start of the year. Since then, ABEO stock has increased by 17.2% and is now trading at $3.61.
View the best growth stocks for 2023 here
.

Are investors shorting Abeona Therapeutics?

Abeona Therapeutics saw a increase in short interest in the month of August. As of August 31st, there was short interest totaling 500,500 shares, an increase of 13.2% from the August 15th total of 442,000 shares. Based on an average trading volume of 166,400 shares, the short-interest ratio is presently 3.0 days. Approximately 2.2% of the shares of the company are sold short.
View Abeona Therapeutics' Short Interest
.

When is Abeona Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, November 13th 2023.
View our ABEO earnings forecast
.

How were Abeona Therapeutics' earnings last quarter?

Abeona Therapeutics Inc (NASDAQ:ABEO) announced its quarterly earnings results on Tuesday, August, 8th. The biopharmaceutical company reported ($0.44) EPS for the quarter, beating the consensus estimate of ($0.66) by $0.22. The biopharmaceutical company had revenue of $3.50 million for the quarter.

When did Abeona Therapeutics' stock split?

Abeona Therapeutics shares reverse split before market open on Tuesday, July 5th 2022. The 1-25 reverse split was announced on Tuesday, July 5th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, July 5th 2022. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

What other stocks do shareholders of Abeona Therapeutics own?
What is Abeona Therapeutics' stock symbol?

Abeona Therapeutics trades on the NASDAQ under the ticker symbol "ABEO."

Who are Abeona Therapeutics' major shareholders?

Abeona Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional investors include Point72 Asset Management L.P. (6.02%), Goldman Sachs Group Inc. (1.14%), Citigroup Inc. (1.06%), Geode Capital Management LLC (0.84%), BlackRock Inc. (0.76%) and Northern Trust Corp (0.55%). Insiders that own company stock include Brendan M O'malley, Edward Carr, Joseph Walter Vazzano, Mark Alvino, Michael Amoroso, Paul Elliot Mann, Sco Capital Partners Llc and Todd Wider.
View institutional ownership trends
.

How do I buy shares of Abeona Therapeutics?

Shares of ABEO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Abeona Therapeutics' stock price today?

One share of ABEO stock can currently be purchased for approximately $3.61.

How much money does Abeona Therapeutics make?

Abeona Therapeutics (NASDAQ:ABEO) has a market capitalization of $89.38 million and generates $1.41 million in revenue each year.

How can I contact Abeona Therapeutics?

Abeona Therapeutics' mailing address is 3333 LEE PARKWAY SUITE 600, DALLAS TX, 75219. The official website for the company is www.abeonatherapeutics.com. The biopharmaceutical company can be reached via phone at 214-665-9495, via email at ir@abeonatherapeutics.com, or via fax at 214-905-5101.

This page (NASDAQ:ABEO) was last updated on 9/22/2023 by MarketBeat.com Staff

My Account -